+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Huntington Disease Treatment Market, Size, Share, Global Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Company Analysis

  • ID: 5576808
  • Report
  • April 2022
  • Region: Global
  • 130 Pages
  • Renub Research
Global Huntington's disease Treatment Market will reach US$ 1,458.83 Million by 2027. Huntington's Disease (HD) is a hereditary neurodegenerative disease driven by an expansion of a repeating CAG triplet series in the huntingtin gene (HTT) on chromosome 4, which results in a protein with an abnormally long polyglutamine sequence. Moreover, HD is one of a more prominent family of polyglutamine repeat diseases, all of which are neurodegenerative diseases. It is inherited in an autosomal dominant fashion so that each child of an affected parent has a 50% chance of developing the disorder.



Trends Shaping the Global Huntington's Disease Treatment Market Size:


Globally, the rising prevalence of rare genetic disorders amongst the metropolitan population has grown the incidence of Huntington's disease, with key healthcare stakeholders like Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and others attempting to discover novel medicinal approaches, providing a platform for manufacturers to expand their influence in the global market.


However, due to the global COVID-19, the Huntington's disease treatment market's growth rate slowed from 2019-2020. Online pharmacies' distribution channel was selling off-label drugs to manage HD symptoms during the pandemic, such as antidepressants, antipsychotics, and anticonvulsants. As a result of the government-imposed lockdown, clinical trials were postponed during the COVID-19 pandemic.


Besides, the market is anticipated to grow between 2022 and 2023. As of 2021, most hospitals and clinics globally reported increased clinical visits for HD treatment. Ingrezza's has developed its label to include chorea associated with Huntington's disorder. Owning to the increased incidence of HD in western countries. These are expected to be significant market drivers. As per the analysis, Global Huntington's Disease Treatment Market Size is Expanding at a CAGR of 23.81% During 2021-2027.

Global Huntington's disease Treatment Industry was US$ 405.03 Million in 2021:


Based on Treatment Type, the symptomatic treatment segment holds the significant market share. This growth is because of the availability of symptom management products and patent protection for these products. Xenazine and Austedo are assessed as first-line therapy for chorea linked with Huntington's disease. The R&D of potential product candidates for symptom management of Huntington's disease may contribute to segment growth. In October 2021, the U.S. FDA approved orphan drug designation for SOM BIOTECH's drug SOM3355 to treat chorea associated with Huntington's condition. As a result, the product has exclusivity for 7 years upon U.S. FDA approval.

Geographically, North America holds the dominant market in the Huntington's disease treatment market:


In North America, there is a massive demand for Huntington's disease treatment due to the increased burden of the disease, technological advancements, increased healthcare expenditure, proactive government initiatives, and raised patient awareness about treatment products for Huntington's disease.

Similarly, in the Asia Pacific, Huntington's disease treatment market is anticipated to witness significant growth over the coming year due to untapped potential, increased product penetration, and the growing preponderance of the disease in emerging countries over the forecast period. An increasing number of initiatives being undertaken by governments to improve the population's health status is anticipated to drive the growth of the HD treatment market in the region.

Key Players and Market Share Insights:


Key players like Pfizer Inc, Bausch Health Cos, Dr. Reddy's Laboratories, H Lundbeck, Hikma Pharmaceuticals Plc, Sun Pharmaceutical Industries Limited, Lupin Ltd., and Alnylam Pharmaceuticals are contributing to market development by adopting various strategies like new product launches and partnerships to gain higher market revenue.

The report titled Global Huntington’s Disease Treatment Market by Treatment Type (Symptomatic Therapy and Disease-modifying Therapy), Drug Type (Antidopaminergic, Anticonvulsants, Antipsychotics, Antidepressants), End-User (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Others), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Pfizer Inc, Bausch Health Cos, Dr Reddy's Laboratories, H Lundbeck, Hikma Pharmaceuticals Plc, Sun Pharmaceutical Industries Limited, Lupin Ltd. and Alnylam Pharmaceuticals)” provides a complete analysis of Global Huntington’s Disease Treatment Industry.

Treatment Type - the Market has been covered from 2 viewpoints:


1. Symptomatic Therapy
2. Disease-modifying Therapy

Drug Type - the Markethas been covered from 4 viewpoints:


1. Antidopaminergic
2. Anticonvulsants
3. Antipsychotics
4. Antidepressants

End User - the Market has been covered from 4 viewpoints:


1. Hospital Pharmacies
2. Specialty Pharmacies
3. Retail Pharmacies
4. Others

Region - the Market has been covered from 5 viewpoints:


1. North America
2. Europe
3. Asia Pacific
4. Latin America
5. Middle East & Africa

Company Insights:


  • Overview
  • Recent Development
  • Revenue

Company Analysis:


1. Pfizer Inc
2. Bausch Health Cos
3. Dr Reddy's Laboratories
4. H Lundbeck
5. Hikma Pharmaceuticals Plc
6. Sun Pharmaceutical Industries Limited
7. Lupin Ltd.
8. Alnylam Pharmaceuticals
Frequently Asked Questions about the Global Huntington Disease Treatment Market, Share

What is the estimated value of the Global Huntington Disease Treatment Market, Share?

The Global Huntington Disease Treatment Market, Share was estimated to be valued at $405.0 Million in 2021.

What is the growth rate of the Global Huntington Disease Treatment Market, Share?

The growth rate of the Global Huntington Disease Treatment Market, Share is 23.8%, with an estimated value of $1458.8 Million by 2027.

What is the forecasted size of the Global Huntington Disease Treatment Market, Share?

The Global Huntington Disease Treatment Market, Share is estimated to be worth $1458.8 Million by 2027.

Table of Contents

1. Introduction2. Research & Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Huntington’s Disease Treatment Market
6. GlobalHuntington’s Disease Treatment Market - Share Analysis
6.1 By Treatment Type
6.2 By Drug Type
6.3 By End User
6.4 By Region
7. Global Huntington’s Disease Treatment Market- By Treatment Type
7.1 Symptomatic Therapy
7.2 Disease-modifying Therapy
8. Global Huntington’s Disease Treatment Market- By Drug Type
8.1 Antidopaminergic
8.2 Anticonvulsants
8.3 Antipsychotics
8.4 Antidepressants
9. Global Huntington’s Disease Treatment Market- By End User
9.1 Hospital Pharmacies
9.2 Specialty Pharmacies
9.3 Retail Pharmacies
9.4 Others
10. Global Huntington’s Disease Treatment Market- By Region
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America
10.5 Middle East & Africa
11. Porters Five Forces
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Competition
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. Key Players
12.1 Pfizer Inc.
12.1.1 Overview
12.1.2 Recent Development
12.1.3 Revenue
12.2 Bausch Health Cos
12.2.1 Overview
12.2.2 Recent Development
12.2.3 Revenue
12.3 Dr Reddy's Laboratories
12.3.1 Overview
12.3.2 Recent Development
12.3.3 Revenue
12.4 H Lundbeck
12.4.1 Overview
12.4.2 Recent Development
12.4.3 Revenue
12.5 Hikma Pharmaceuticals Plc
12.5.1 Overview
12.5.2 Recent Development
12.5.3 Revenue
12.6 Sun Pharmaceutical Industries Limited
12.6.1 Overview
12.6.2 Recent Development
12.6.3 Revenue
12.7 Lupin Ltd.
12.7.1 Overview
12.7.2 Recent Development
12.7.3 Revenue
12.8 Alnylam Pharmaceuticals
12.8.1 Overview
12.8.2 Recent Development
12.8.3 Revenue
List of Figures:
Figure 01: Global - Huntington’s Disease Treatment Market (Million US$), 2016 - 2021
Figure 02: Global - Forecast for Huntington’s Disease Treatment Market (Million US$), 2022 - 2027
Figure 03: Treatment Type - Symptomatic Therapy Market (Million US$), 2016 - 2021
Figure 04: Treatment Type - Forecast for Symptomatic Therapy Market (Million US$), 2022 - 2027
Figure 05: Treatment Type - Disease-modifying Therapy Market (Million US$), 2016 - 2021
Figure 06: Treatment Type - Forecast for Disease-modifying Therapy Market (Million US$), 2022 - 2027
Figure 07: Drug Type - Antidopaminergic Market (Million US$), 2016 - 2021
Figure 08: Drug Type - Forecast for Antidopaminergic Market (Million US$), 2022 - 2027
Figure 09: Drug Type - Anticonvulsants Market (Million US$), 2016 - 2021
Figure 10: Drug Type - Forecast for Anticonvulsants Market (Million US$), 2022 - 2027
Figure 11: Drug Type - Antipsychotics Market (Million US$), 2016 - 2021
Figure 12: Drug Type - Forecast for Antipsychotics Market (Million US$), 2022 - 2027
Figure 13: Drug Type - Antidepressants Market (Million US$), 2016 - 2021
Figure 14: Drug Type - Forecast for Antidepressants Market (Million US$), 2022 - 2027
Figure 15: End User - Hospital Pharmacies Market (Million US$), 2016 - 2021
Figure 16: End User - Forecast for Hospital Pharmacies Market (Million US$), 2022 - 2027
Figure 17: End User - Specialty Pharmacies Market (Million US$), 2016 - 2021
Figure 18: End User - Forecast for Specialty Pharmacies Market (Million US$), 2022 - 2027
Figure 19: End User - Retail Pharmacies Market (Million US$), 2016 - 2021
Figure 20: End User - Forecast for Retail Pharmacies Market (Million US$), 2022 - 2027
Figure 21: End User - Others Market (Million US$), 2016 - 2021
Figure 22: End User - Forecast for Others Market (Million US$), 2022 - 2027
Figure 23: North America - Huntington’s Disease Treatment Market (Million US$), 2016 - 2021
Figure 24: North America - Forecast for Huntington’s Disease Treatment Market (Million US$), 2022 - 2027
Figure 25: Europe - Huntington’s Disease Treatment Market (Million US$), 2016 - 2021
Figure 26: Europe - Forecast for Huntington’s Disease Treatment Market (Million US$), 2022 - 2027
Figure 27: Asia Pacific - Huntington’s Disease Treatment Market (Million US$), 2016 - 2021
Figure 28: Asia Pacific - Forecast for Huntington’s Disease Treatment Market (Million US$), 2022 - 2027
Figure 29: Latin America - Huntington’s Disease Treatment Market (Million US$), 2016 - 2021
Figure 30: Latin America - Forecast for Huntington’s Disease Treatment Market (Million US$), 2022 - 2027
Figure 31: Middle East & Africa - Huntington’s Disease Treatment Market (Million US$), 2016 - 2021
Figure 32: Middle East & Africa - Forecast for Huntington’s Disease Treatment Market (Million US$), 2022 - 2027
Figure 33: Pfizer Inc. - Global Revenue (Million US$), 2016 - 2021
Figure 34: Pfizer Inc. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 35: Bausch Health Cos - Global Revenue (Million US$), 2016 - 2021
Figure 36: Bausch Health Cos - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 37: Dr Reddy's Laboratories - Global Revenue (Million US$), 2016 - 2021
Figure 38: Dr Reddy's Laboratories - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 39: H Lundbeck - Global Revenue (Million US$), 2016 - 2021
Figure 40: H Lundbeck - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 41: Hikma Pharmaceuticals Plc - Global Revenue (Million US$), 2016 - 2021
Figure 42: Hikma Pharmaceuticals Plc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 43: Sun Pharmaceutical Industries Limited - Global Revenue (Million US$), 2016 - 2021
Figure 44: Sun Pharmaceutical Industries Limited - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 45: Lupin Ltd. - Global Revenue (Million US$), 2016 - 2021
Figure 46: Lupin Ltd. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 47: Alnylam Pharmaceuticals - Global Revenue (Million US$), 2016 - 2021
Figure 48: Alnylam Pharmaceuticals - Forecast for Global Revenue (Million US$), 2022 - 2027
List of Tables:
Table 01: Global - Huntington’s Disease Treatment Market Share by Treatment Type (Percent), 2016 - 2021
Table 02: Global - Forecast for Huntington’s Disease Treatment Market Share by Treatment Type (Percent), 2022 - 2027
Table 03: Global - Huntington’s Disease Treatment Market Share by Drug Type (Percent), 2016 - 2021
Table 04: Global - Forecast for Huntington’s Disease Treatment Market Share by Drug Type (Percent), 2022 - 2027
Table 05: Global - Huntington’s Disease Treatment Market Share by End-User (Percent), 2016 - 2021
Table 06: Global - Forecast for Huntington’s Disease Treatment Market Share by End-User (Percent), 2022 - 2027
Table 07: Global - Huntington’s Disease Treatment Market Share by Region (Percent), 2016 - 2021
Table 08: Global - Forecast for Huntington’s Disease Treatment Market Share by Region (Percent), 2022 - 2027
List of Figures

Companies Mentioned

  • Pfizer Inc
  • Bausch Health Cos
  • Dr Reddy's Laboratories
  • H Lundbeck
  • Hikma Pharmaceuticals Plc
  • Sun Pharmaceutical Industries Limited
  • Lupin Ltd.
  • Alnylam Pharmaceuticals

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...